OR WAIT null SECS
Richard Denk is Head Sales Containment at SKAN AG, www.skan.ch, Richard.Denk@skan.ch.
Decontamination, automation, and containment are important considerations for aseptic manufacturing in isolators.
A revised draft of the European Union (EU) good manufacturing practice (GMP) Annex 1 was published in February 2020 (1), and a final version is expected in 2021. The GMP guidance includes several key points related to isolator design and operation, which are illustrated in Figure 1.
As the author discussed in the first part of this article series, the design of an isolator is the basis for compliance with GMP in aseptic processing and in cleanability (2). Isolator design also affects surface decontamination.
Hygienic design and cleaning to remove particulate and microbiological contamination are important attributes for surface decontamination of the inner surfaces of isolators and of their installations (e.g., a vial or syringe filling line, an incubator, or other utilities for manufacturing cell and gene therapies). Consider section 4.24 of the new EU Draft GMP Annex 1, which says (1):
For RABS [restricted access barrier systems] and isolator systems, decontamination methods should be validated and controlled within defined cycle parameters. The cleaning process prior to the disinfection step is essential; any residues that remain may inhibit the effectiveness of the decontamination process:
i. For isolators, the decontamination process should be automated and should include a sporicidal agent in a suitable form (e.g., gaseous, aerosolized, or vaporized form) to ensure thorough microbial decontamination of its interior. Decontamination methods (cleaning and sporicidal disinfection) should render the interior surfaces and critical zone of the isolator free of viable microorganisms. (1)
This section has two messages in terms of isolators: decontamination methods should be validated and controlled within defined cycle parameters and the process should be automated and should use a sporicidal agent.
In most isolators, surface decontamination is carried out with vaporized or sprayed hydrogen peroxide (H2O2) as the sporicidal agent. Direct spraying of micro-nebulized H2O2 into the isolator system produces a quick distribution with a smaller amount compared to vaporizing H2O2.
The decontamination cycle, using the selected agent, must be validated in accordance with GMP to generate a reliably aseptic atmosphere inside the isolator. The phrase “controlled with defined cycle parameters” does not mean solely the amount and time of the H2O2 in the isolator system; the following questions should be considered:
The phrase “defined cycle parameter” also contains quality-by-design (QbD) attributes in regards to the variable parameters in the isolator system. Consider questions such as the following when developing a validated decontamination cycle:
Automation, including robotics, can make manufacturing of sterile products more efficient, quicker, and safer. Robotic systems are mentioned specifically in section 2.1 of the new EU Draft GMP Annex 1, which says (1):
The manufacture of sterile products is subject to special requirements in order to minimize risk of microbial, particulate and pyrogen contamination. The following key areas should be considered:
i. Facility, equipment and process design should be optimized, qualified, and validated according to the relevant sections of the Good Manufacturing Practices (GMP) guide. The use of appropriate technologies (e.g., Restricted Access Barriers Systems (RABS), isolators, robotic systems, rapid microbial testing and monitoring systems) should be considered to increase the protection of the product from potential extraneous sources of particulate and microbial contamination such as personnel, materials and the surrounding environment, and assist in the rapid detection of potential contaminants in the environment and product. (1)
Robotic work processes are widely used in pharmaceutical packaging, and their use has been expanding; they are now employed for handling sterile products, free of any manual interventions. The International Society for Pharmaceutical Engineering (ISPE) DACH [Germany/Austria/Switzerland] Future Robotics special interest group (SIG) was founded by the author in 2019. The SIG concerns itself with possible new work processes for robotic systems, the facility of the future using robotics, and the regulatory requirements from the EU GMP Annex 1 Draft for using robotics.
For example, a new work process for robotic systems is to place molded parts in transport containers and transport them to the washing machine and, after washing, back to the isolator. This process needs to take into account transfers between individual cleanroom grades.
Another work process is aseptic filling and automated handling of sterile finished products by means of robotic systems in isolators, as well as implementing their technical and regulatory compliance with current good manufacturing practice (CGMP). It is necessary, for example, to adapt viable monitoring to fully automated robotic solutions in aseptic manufacture. In the Draft Annex 1, the application of rapid microbial monitoring is mentioned, but the technical and organizational measures needed to replace the current monitoring methods using settle plates with rapid microbial testing methods need to be redefined. This topic will be addresed by the ISPE Future Robotics SIG in 2021.
The production of highly active and hazardous substances in the biopharmaceutical industry has increased rapidly in recent years, requiring consideration of environment, health, and safety protection. Viral vectors, for example, require high protection for the employee as well as prevention of cross-contamination with other substances.
Consider section 4.14 of the new EU Draft GMP Annex 1, which says, regarding the topic of containment of highly active and dangerous substances (1):
… Particular attention should be paid to the protection of the critical zone. The recommendations regarding air supplies and pressures may need to be modified where it is necessary to contain certain materials (e.g., pathogenic, highly toxic or radioactive products or live viral or bacterial materials)…(1)
In addition to the pressure concept, the following aspects need to be taken into consideration for fill/finish of parenteral pharmaceuticals in an isolator system:
1. EC, Draft Revision to “Annex 1, Manufacture of Sterile Medicinal Products,” (Brussels, 2020).
2. R. Denk, Pharm. Tech. 44 (11) 34-37 (2020).
3. EMA, Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities, EMA/CHMP/CVMP/ SWP/169430/2012 (London, 2014).
Richard Denk is senior consultant for Aseptic Processing and Containment at SKAN in Switzerland and is a member of the ISPE Commenting Team of the new draft of EU GMP Annex 1.
Vol. 45, No. 4
When referring to this article, please cite it as R. Denk, “Understanding the Impact of Annex 1 on Isolator Operation,” Pharmaceutical Technology 45 (4) 2021.